Studies on the role and mechanism of methotrexate in lowering blood uric acid in patients with rheumatic and musculoskeletal diseases

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500096918

Enrollment

Unknown

Registered

2025-02-08

Start date

2025-03-01

Completion date

Unknown

Last updated

2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperuricacidemia

Interventions

Taking MTX group:Add 1mg / L MXT cell culture, detection of ADA and AICAR converting enzyme content.

healthy controls:Blank cell culture, detection of ADA and AICAR converting enzyme content.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. patients with definite diagnosis of rheumatic and musculoskeletal diseases ; 2.Patients with rheumatic and musculoskeletal diseases RMDs who took low-dose methotrexate for the first time ;

Exclusion criteria

Exclusion criteria: 1.Combined use of drugs that interfere with renal urate treatment and those that may affect uric acid metabolism Antirheumatic drugs such as leflunomide ; 2.Patients refused to be included in the study ; 3.The researchers judged the inappropriate candidates.

Design outcomes

Primary

Measure	Time frame
uric acid;Serum ADA content;	—

Countries

China

Contacts

Public ContactWang Guihong

Department of Rheumatology, Anqing Hospital Affiliated to Anhui Medical University

aqfsmy2010@163.com+86 138 6644 9332

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026